Company: ARVN
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001655759-25-000139
Chunk: 160

Company: ARVINAS, INC.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 8
Chunk 160
---
 Report on Form 10-K for the year ended December 31, 2024 and in Note 2, Summary of Accounting Pronouncements and Significant Accounting Policies. The chief operating decision maker evaluates the performance of the operating segment and allocates resources based on net income/loss that also is reported on the consolidated income statement as net income (loss). The measure of the operating segment assets is reported on the consolidated balance sheet as total assets.The chief operating decision maker uses net loss to monitor budget versus actual results and to analyze cash flows in assessing performance of the segment and allocating resources.The following table summarizes the reportable segment's financial information: Three Months EndedJune 30,Six Months EndedJune 30,(dollars in millions)2025202420252024Revenue$22.4 $76.5 $211.2 $101.8 Less:Research and development expenseVepdegestrant (ARV-471) (*)15.1 25.1 39.2 44.1 ARV-1023.8 1.7 10.3 3.0 ARV-3932.5 1.7 5.1 2.9 ARV-806 1.7 0.2 2.6 0.3 Bavdegalutamide (ARV-110)0.9 2.5 2.0 4.1 Luxdegalutamide (ARV-766)— 9.5 — 13.2 Other programs0.8 — 2.5 — Non program-specific external expense11.1 13.5 25.0 29.6 Compensation and related personnel expense(including stock-based compensation)28.4 36.3 65.3 74.6 Other research and development expense4.3 3.2 7.4 6.2 Total research and development expense68.6 93.7 159.4 178.0 General and administrative expense25.3 31.3 51.9 55.6 Other segment expense, net (**)0.3 0.1 0.4 0.1 Income tax expense(0.3)0.2 (0.2)0.3 Plus:Interest income, net10.3 13.6 22.0 27.6 Segment net (